Seminars in Hematology
Volume 44, Issue 2 , Pages 70-76 , April 2007

Hyperhomocysteinemia and Venous Thrombosis

  • Alex Gatt
    • ,
  • Michael Makris

      Affiliations

    • Corresponding Author InformationAddress correspondence to Michael Makris, MA, MD, FRCP, FRCPath, Sheffield Haemophilia and Thrombosis Centre, Royal Hallamshire Hospital, Glossop Road, Sheffield, UK S10 2JF.

References 

  1. Carson NA, Neill DW. Metabolic abnormalities detected in a survey of mentally backward individuals in Northern Ireland. Arch Dis Child. 1962;37:505–513
  2. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet. 1985;37:1–31
  3. Fowler B. Homocysteine: Overview of biochemistry, molecular biology, and role in disease processes. Semin Vasc Med. 2005;5:77–86
  4. Shipchandler MT, Moore EG. Rapid, fully automated measurement of plasma homocyst(e)ine with the Abbott IMx analyzer. Clin Chem. 1995;41:991–994
  5. Still RA, McDowell IF. Clinical implications of plasma homocysteine measurement in cardiovascular disease. ACP Broadsheet No 152: March 1998 J Clin Pathol. 1998;51:183–188
  6. Dudman NP. An alternative view of homocysteine. Lancet. 1999;354:2072–2074
  7. Watanabe M, Osada J, Aratani Y, Kluckman K, Reddick R, Malinow MR, et al. Mice deficient in cystathionine beta-synthase: Animal models for mild and severe homocyst(e)inemia. Proc Natl Acad Sci U S A. 1995;92:1585–1589
  8. Dayal S, Wilson KM, Leo L, Arning E, Bottiglieri T, Lentz SR. Enhanced susceptibility to arterial thrombosis in a murine model of hyperhomocysteinemia. Blood. 2006;108:2237–2243
  9. Lentz SR, Sobey CG, Piegors DJ, Bhopatkar MY, Faraci FM, Malinow MR, et al. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest. 1996;98:24–29
  10. Dayal S, Bottiglieri T, Arning E, Maeda N, Malinow MR, Sigmund CD, et al. Endothelial dysfunction and elevation of S-adenosylhomocysteine in cystathionine beta-synthase-deficient mice. Circ Res. 2001;88:1203–1209
  11. Undas A, Williams EB, Butenas S, Orfeo T, Mann KG. Homocysteine inhibits inactivation of factor Va by activated protein C. J Biol Chem. 2001;276:4389–4397
  12. Podda G, Faioni EM, Zighetti ML, Cattaneo M. No effect of fasting plasma total homocysteine on protein C activity in vitro. Blood. 2003;101:2446–2447
  13. Zarychanski R, Houston DS. Plasma homocysteine concentration is not associated with activated protein C resistance in patients investigated for hypercoagulability. Thromb Haemost. 2004;91:1115–1122
  14. Hajjar KA, Mauri L, Jacovina AT, Zhong F, Mirza UA, Padovan JC, et al. Tissue plasminogen activator binding to the annexin II tail domain (Direct modulation by homocysteine). J Biol Chem. 1998;273:9987–9993
  15. Hajjar KA, Jacovina AT. Modulation of annexin II by homocysteine: Implications for atherothrombosis. J Investig Med. 1998;46:364–369
  16. Kaufman RJ. Orchestrating the unfolded protein response in health and disease. J Clin Invest. 2002;110:1389–1398
  17. Leoncini G, Bruzzese D, Signorello MG. Activation of p38 MAPKinase/cPLA2 pathway in homocysteine-treated platelets. J Thromb Haemost. 2006;4:209–216
  18. Luo F, Liu X, Wang S, Chen H. Effect of homocysteine on platelet activation induced by collagen. Nutrition. 2006;22:69–75
  19. Riba R, Nicolaou A, Troxler M, Homer-Vaniasinkam S, Naseem KM. Altered platelet reactivity in peripheral vascular disease complicated with elevated plasma homocysteine levels. Atherosclerosis. 2004;175:69–75
  20. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 1998;338:1042–1050
  21. Upchurch GR, Welch GN, Fabian AJ, Freedman JE, Johnson JL, Keaney JF, et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem. 1997;272:17012–17017
  22. Ruud E, Holmstrom H, Brosstad F, Wesenberg F. Children with acute lymphoblastic leukaemia have high plasma levels of total homocysteine at time of diagnosis. Scand J Clin Lab Invest. 2006;66:67–78
  23. Kang SS, Zhou J, Wong PW, Kowalisyn J, Strokosch G. Intermediate homocysteinemia: A thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet. 1988;43:414–421
  24. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111–113
  25. Ma J, Stampfer MJ, Hennekens CH, Frosst P, Selhub J, Horsford J, et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation. 1996;94:2410–2416
  26. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 1996;93:7–9
  27. Hessner MJ, Luhm RA, Pearson SL, Endean DJ, Friedman KD, Montgomery RR. Prevalence of prothrombin G20210A, factor V G1691A (Leiden), and methylenetetrahydrofolate reductase (MTHFR) C677T in seven different populations determined by multiplex allele-specific PCR. Thromb Haemost. 1999;81:733–738
  28. Den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: A meta-analysis of published epidemiological studies. J Thromb Haemost. 2005;3:292–299
  29. Philipp CS, Dilley A, Saidi P, Evatt B, Austin H, Zawadsky J, et al. Deletion polymorphism in the angiotensin-converting enzyme gene as a thrombophilic risk factor after hip arthroplasty. Thromb Haemost. 1998;80:869–873
  30. Joseph JE, Low J, Courtenay B, Neil MJ, McGrath M, Ma D. A single-centre prospective study of clinical and haemostatic risk factors for venous thromboembolism following lower limb arthroplasty. Br J Haematol. 2005;129:87–92
  31. Walker ID, Greaves M, Preston FE. Investigation and management of heritable thrombophilia. Br J Haematol. 2001;114:512–528
  32. Bienvenu T, Ankri A, Chadefaux B, Kamoun P. [Plasma homocysteine assay in the exploration of thrombosis in young subjects]. Presse Med. 1991;20:985–988
  33. Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation. 1997;95:1777–1782
  34. Eichinger S, Stumpflen A, Hirschl M, Bialonczyk C, Herkner K, Stain M, et al. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost. 1998;80:566–569
  35. Tsai AW, Cushman M, Tsai MY, Heckbert SR, Rosamond WD, Aleksic N, et al. Serum homocysteine, thermolabile variant of methylene tetrahydrofolate reductase (MTHFR), and venous thromboembolism: Longitudinal Investigation of Thromboembolism Etiology (LITE). Am J Hematol. 2003;72:192–200
  36. den Heijer M, Willems HP, Blom HJ, Cattaneo M, Gerrits WB, Eichinger S, et al. Homocysteine lowering by B vitamins and the secondary prevention of deep-vein thrombosis and pulmonary embolism (A randomized, placebo-controlled, double blind trial). Blood. 2007;109:139–144
  37. David R, Zangwill L, Badarna M, Yassur Y. Epidemiology of retinal vein occlusion and its association with glaucoma and increased intraocular pressure. Ophthalmologica. 1988;197:69–74
  38. Janssen MC, den Heijer M, Cruysberg JR, Wollersheim H, Bredie SJ. Retinal vein occlusion: A form of venous thrombosis or a complication of atherosclerosis? (A meta-analysis of thrombophilic factors). Thromb Haemost. 2005;93:1021–1026
  39. Li XM, Wei YF, Hao HL, Hao YB, He LS, Li JD, et al. Hyperhomocysteinemia and the MTHFR C677T mutation in Budd-Chiari syndrome. Am J Hematol. 2002;71:11–14
  40. Primignani M, Martinelli I, Bucciarelli P, Battaglioli T, Reati R, Fabris F, et al. Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology. 2005;41:603–608
  41. Heller C, Schobess R, Kurnik K, Junker R, Gunther G, Kreuz W, et al. Childhood Thrombophilia Study Group Abdominal venous thrombosis in neonates and infants: Role of prothrombotic risk factors - a multicentre case-control study. Br J Haematol. 2000;111:534–539
  42. Kosch A, Kuwertz-Broking E, Heller C, Kurnik K, Schobess R, Nowak-Gottl U. Renal venous thrombosis in neonates: Prothrombotic risk factors and long-term follow-up. Blood. 2004;104:1356–1360
  43. Dentali F, Crowther M, Ageno W. Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: A meta-analysis. Blood. 2006;107:2766–2773
  44. Koch HG, Nabel P, Junker R, Auberger K, Schobess R, Homberger A, et al. The 677T genotype of the common MTHFR thermolabile variant and fasting homocysteine in childhood venous thrombosis. Eur J Pediatr. 1999;158(suppl 3):S113–S116
  45. Kosch A, Koch HG, Heinecke A, Kurnik K, Heller C, Nowak-Gottl U. Increased fasting total homocysteine plasma levels as a risk factor for thromboembolism in children. Thromb Haemost. 2004;91:308–314
  46. Daly S, Cotter A, Molloy AE, Scott J. Homocysteine and folic acid: Implications for pregnancy. Semin Vasc Med. 2005;5:190–200
  47. Refsum H, Nurk E, Smith AD, Ueland PM, Gjesdal CG, Bjelland I, et al. The Hordaland Homocysteine Study: A community-based study of homocysteine, its determinants, and associations with disease. J Nutr. 2006;136:1731S–1740S
  48. Holmes VA. Changes in haemostasis during normal pregnancy: Does homocysteine play a role in maintaining homeostasis?. Proc Nutr Soc. 2003;62:479–493
  49. Meglic L, Stegnar M, Milanez T, Bozic M, Peterlin B, Peternel P, et al. Factor V Leiden, prothrombin 20210G→A, methylenetetrahydrofolate reductase 677C→T and plasminogen activator inhibitor 4G/5G polymorphism in women with pregnancy-related venous thromboembolism. Eur J Obstet Gynecol Reprod Biol. 2003;111:157–163
  50. Ogunyemi D, Cuellar F, Ku W, Arkel Y. Association between inherited thrombophilias, antiphospholipid antibodies, and lipoprotein A levels and venous thromboembolism in pregnancy. Am J Perinatol. 2003;20:17–24
  51. Wu O, Robertson L, Twaddle S, Lowe GD, Clark P, Greaves M, et al. Screening for thrombophilia in high-risk situations: Systematic review and cost-effectiveness analysis (The Thrombosis Risk and Economic Assessment of Thrombophilia Screening (TREATS) study). Health Technol Assess. 2006;10:1–110
  52. Yap S, Naughten E. Homocystinuria due to cystathionine beta-synthase deficiency in Ireland: 25 years’ experience of a newborn screened and treated population with reference to clinical outcome and biochemical control. J Inherit Metab Dis. 1998;21:738–747
  53. Yap S, Boers GH, Wilcken B, Wilcken DE, Brenton DP, Lee PJ, et al. Vascular outcome in patients with homocystinuria due to cystathionine beta-synthase deficiency treated chronically: A multicenter observational study. Arterioscler Thromb Vasc Biol. 2001;21:2080–2085
  54. Homocysteine Lowering Trialists’ Collaboration. Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomised trials. BMJ. 1998;316:894–898
  55. Eberhardt RT, Forgione MA, Cap A, Leopold JA, Rudd MA, Trolliet M, et al. Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. J Clin Invest. 2000;106:483–491
  56. Woo KS, Chook P, Chan LL, Cheung AS, Fung WH, Qiao M, et al. Long-term improvement in homocysteine levels and arterial endothelial function after 1-year folic acid supplementation. Am J Med. 2002;112:535–539
  57. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: The Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004;291:565–575
  58. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354:1567–1577
  59. Liebson PR. Women’s Health Initiative (WHI) Dietary Trial and Norwegian Vitamin Trial (NORVIT). Prev Cardiol. 2006;9:178–182

PII: S0037-1963(07)00003-0

doi: 10.1053/j.seminhematol.2007.01.002

Seminars in Hematology
Volume 44, Issue 2 , Pages 70-76 , April 2007

Article Tools

* Image Usage & Resolution